معرفی
Professor David Rubinsztein is a leading figure in molecular neurogenetics at the University of Cambridge, where he serves as Deputy Director of the Cambridge Institute for Medical Research (CIMR) and UK Dementia Research Institute Group Leader. His research focuses on autophagy and its role in neurodegenerative diseases like Alzheimer’s, Parkinson’s, and Huntington’s Disease. He has pioneered strategies to upregulate autophagy as a therapeutic approach, identifying novel drugs and pathways.
- Key affiliations: UK Dementia Research Institute, Alzheimer’s Research UK ALBORADA Drug Discovery Institute
- Funding sources: Wellcome Trust, National Institute for Health Research, Parkinson’s UK, Tau Consortium
His work bridges basic cell biology with translational research in neurodegeneration and rare genetic diseases.
Scientific awards include the Graham Bull Prize (2007), Thudichum Medal (2017), Roger de Spoelberch Prize (2017), Goudie Medal (2020), and recognition as a Clarivates Analytics Highly Cited Researcher (2018-2023). He is a Fellow of the Royal Society, EMBO, and the Academy of Medical Sciences.
